Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates

Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3039 · Cited by 469

The Role of Glial Reaction and Inflammation in Parkinson's Disease

Hirsch, É. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., & Michel, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 455

Brain macrophages: evaluation of microglia and their functions

Thomas, W. E. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90007-9 · Cited by 441

Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases

Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445

Parkinson’s Disease

Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire‐Zeiss, K. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 463

Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons

Gao, H., Hong, J., Zhang, W., & Liu, B. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00782.2002 · Cited by 439

Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration

Gao, H., Kotzbauer, P. T., Uryu, K., Leight, S., Trojanowski, J. Q., & Lee, V. M. ‐. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0143-07.2008 · Cited by 453

Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review

Bacchi, S., Palumbo, P., Sponta, A. M., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 457

Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders

Reynolds, A., Laurie, C. D., Mosley, R. L., & Gendelman, H. E. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82016-2 · Cited by 441

MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration

Lee, E., Hwang, I., Park, S., Hong, S., Hwang, B., Cho, Y., Son, J., & Yu, J.-W. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0124-5 · Cited by 431

Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease

Gelders, G., Baekelandt, V., & Van der Perren, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4784268 · Cited by 430

Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's disease

Banati, R. B., Daniel, S. E., & Blunt, S. B. (1998) · Movement Disorders · doi:10.1002/mds.870130205 · Cited by 430

The impact of systemic infection on the progression of neurodegenerative disease

Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428

Glia: Initiators and progressors of pathology in Parkinson's disease

Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 436

Role of Nitric Oxide in Inflammation‐Mediated Neurodegeneration

Liu, B., Gao, H., Wang, J., Jeohn, G., Cooper, C. L., & Hong, J. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04077.x · Cited by 425

Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease

Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Mosley, R. L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 423

Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition

Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414

Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice

Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 412

The Significance of Vasoactive Intestinal Peptide in Immunomodulation

Delgado, M., Pozo, D., & Ganea, D. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.7 · Cited by 415

The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy

Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411

Kynurenines in CNS disease: regulation by inflammatory cytokines.

Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409

MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration

Harms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., Cron, R. Q., Shacka, J. J., Raman, C., & Standaert, D. G. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5610-12.2013 · Cited by 406

Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging

Cicchetti, F., Brownell, A., Williams, K. S., Chen, Y. I., Livni, E., & Ole Isacson, A. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406

Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease

Freeman, T. B., Olanow, C. W., Hauser, R. A., Nauert, G. M., Smith, D. A., Borlongan, C. V., Sanberg, P. R., Holt, D. A., Kordower, J. H., Vingerhoets, F. J. G., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380307 · Cited by 403

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400

Neuroinflammatory processes in Parkinson's disease

Hunot, S., & Hirsch, É. C. (2003) · Annals of Neurology · doi:10.1002/ana.10481 · Cited by 407

Microglia and astrocyte dysfunction in parkinson's disease

Kam, T., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105028 · Cited by 420

Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System

Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041584.x · Cited by 393

The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic System

Herrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392

Microglia Mediated Neuroinflammation in Parkinson’s Disease

Işık, S., Yeman-Kıyak, B., Akbayır, R., Şeyhali-Abutayeh, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 419

Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease

Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K. M., Laurie, C. D., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 393

Neuroinflammation: Microglia and T Cells Get Ready to Tango

Schetters, S. T. T., Gómez‐Nicola, D., García-Vallejo, J. J., & van Kooyk, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01905 · Cited by 400

The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse

Kurkowska‐Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379

Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease

Breidert, T., Callebert, J., Heneka, M. T., Landreth, G. E., Launay, J., & Hirsch, É. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 381

The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imaging

Venneti, S., Lopresti, B. J., & Wiley, C. A. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.10.002 · Cited by 373

Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes

Li, J., Baud, O., Vartanian, T. K., Volpe, J. J., & Rosenberg, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502552102 · Cited by 370

HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration

Gao, H.-M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., & Hong, J.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3732-10.2011 · Cited by 369

Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease

Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D. P., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 384

Targeted Overexpression of Human α-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease

Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 392

Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System

Montgomery, S. L., & Bowers, W. J. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9287-2 · Cited by 372

Microglia: Agents of the CNS Pro-Inflammatory Response

Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365

FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces,In Vitro,Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells

Hunot, S., Dugas, N., Faucheux, B. A., Hartmann, A., Tardieu, M., Debré, P., Agid, Y., Dugas, B., & Hirsch, É. C. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03440.1999 · Cited by 473

Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation

Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 371

Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons

Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Писарев, В. М., Tsiperson, V., Nemachek, C., Ciborowski, P. S., Przedborski, S., Mosley, R. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001376 · Cited by 371

Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes

Scheiblich, H., Dansokho, C., Mercan, D., Schmidt, S. V., Bousset, L., Wischhof, L., Eikens, F., Odainic, A., Spitzer, J., Griep, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.007 · Cited by 360

Intracellular signaling in M‐CSF‐induced microglia activation: Role of Iba1

Imai, Y., & Kohsaka, S. (2002) · Glia · doi:10.1002/glia.10149 · Cited by 359

Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease

McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 370

Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases

Vegeto, E., Benedusi, V., & Maggi, A. C. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.04.001 · Cited by 364

Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease

Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355

Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease

Koprich, J. B., Reske-Nielsen, C., Mithal, P., & Isacson, O. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-8 · Cited by 355

Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis

Calabrese, V., Santoro, A., Monti, D., Crupi, R., Di Paola, R., Latteri, S., Cuzzocrea, S., Zappia, M., Giordano, J., Calabrese, E. J., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.379 · Cited by 356

The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases

Zipp, F., & Aktaş, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 357

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum

He, Y., Appel, S. H., & Le, W. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02681-6 · Cited by 350

A possible role for humoral immunity in the pathogenesis of Parkinson's disease

Orr, C., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M. (2005) · Brain · doi:10.1093/brain/awh625 · Cited by 367

Naloxone Protects Rat Dopaminergic Neurons against Inflammatory Damage through Inhibition of Microglia Activation and Superoxide Generation

Liu, B., Du, L., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39275-4 · Cited by 347

Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease

Subramaniam, S., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 353

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346

CB2receptors in the brain: role in central immune function

Cabral, G. A., Raborn, E. S., Griffin, L., Dennis, J., & Marciano‐Cabral, F. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707584 · Cited by 361

The two-century journey of Parkinson disease research

Przedborski, S. (2017) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 354

Microglial Dynamics and Role in the Healthy and Diseased Brain: A Paradigm of Functional Plasticity

Gomez-Nicola, D., & Perry, V. H. (2015) · The Neuroscientist · doi:10.1177/1073858414530512 · Cited by 340

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339

MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration

Cebrián, C., Zucca, F. A., Mauri, P., Steinbeck, J. A., Studer, L., Scherzer, C. R., Kanter, E., Budhu, S., Mandelbaum, J., Vonsattel, J. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4633 · Cited by 338

Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models

Ajami, B., Samusik, N., Wieghofer, P., Ho, P. P., Crotti, A., Bjornson, Z., Prinz, M., Fantl, W. J., Nolan, G. P., & Steinman, L. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0100-x · Cited by 338

Critical Role for Microglial NADPH Oxidase in Rotenone-Induced Degeneration of Dopaminergic Neurons

Gao, H., Liu, B., & Hong, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06181.2003 · Cited by 338

Alterations of T-lymphocyte populations in Parkinson disease

Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336

Microglia Phenotypes in Aging and Neurodegenerative Diseases

Wendimu, M. Y., & Hooks, S. B. (2022) · Cells · doi:10.3390/cells11132091 · Cited by 336

Immune Signaling in Neurodegeneration

Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336

Role of cytokines in inflammatory process in Parkinson’s disease

Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331

Research in motion: the enigma of Parkinson's disease pathology spread

Brundin, P., Li, J., Holton, J. L., Lindvall, O., & Révész, T. (2008) · Nature reviews. Neuroscience · doi:10.1038/nrn2477 · Cited by 341

The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease

Mirza, B., Hadberg, H., Thomsen, P., & Moos, T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00455-8 · Cited by 327

The role of glial cells in Parkinsonʼs disease

Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326

Anti-Inflammatory Treatments for Chronic Diseases: A Review

Laveti, D., Kumar, M., Hemalatha, R., Sistla, R., Naidu, V. G. M., Talla, V., Verma, V., Kaur, N., & Nagpal, R. (2013) · Inflammation & Allergy - Drug Targets · doi:10.2174/18715281113129990053 · Cited by 330

Cytokines in Parkinson’s disease

Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6284-2_12 · Cited by 327

CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease

Hutter-Saunders, J. A. L., Estes, K. A., Kosloski, L. M., Allen, H. E., Dempsey, K., Torres‐Russotto, D. R., Meza, J. L., Santamaria, P. M., Bertoni, J. M., Murman, D. L., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9402-z · Cited by 339

Association of circulating TNF-α and IL-6 with ageing and parkinsonism

Dobbs, R. J., Charlett, A., Purkiss, A. G., Dobbs, S. M., Weller, C., & Peterson, D. W. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00721.x · Cited by 324

Solving neurodegeneration: common mechanisms and strategies for new treatments

Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324

Novel anti-inflammatory therapy for Parkinson's disease

Gao, H., Liu, B., Zhang, W., & Hong, J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00176-7 · Cited by 325

Chronic microglial activation and progressive dopaminergic neurotoxicity

Block, M. L., & Hong, J. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351127 · Cited by 331

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V. R., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321

Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases

Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318

Morphometric characterization of microglial phenotypes in human cerebral cortex

Torres-Platas, S. G., Comeau, S., Rachalski, A., Bo, G. D., Cruceanu, C., Turecki, G., Giros, B., & Mechawar, N. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-12 · Cited by 329

Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease

Chen, H., O'Reilly, E. J., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm260 · Cited by 325

Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons

Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R. S., Anisman, H., Hayley, S. P., & Park, D. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 331

Dopamine, Immunity, and Disease

Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J. R., & Gaskill, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 328

Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease

Drechsel, D. A., & Patel, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.008 · Cited by 314

Glutathione—a review on its role and significance in Parkinson's disease

Martin, H. L., & Teismann, P. (2009) · The FASEB Journal · doi:10.1096/fj.08-125443 · Cited by 320

Role of complement in neurodegeneration and neuroinflammation

Bonifati, D. M., & Kishore, U. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 314

Curcumin Suppresses Janus Kinase-STAT Inflammatory Signaling through Activation of Src Homology 2 Domain-Containing Tyrosine Phosphatase 2 in Brain Microglia

Kim, H. Y., Park, E. J., Joe, E.-H., & Jou, I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6072 · Cited by 314

Neurotoxicant-induced animal models of Parkinson?s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration

Uversky, V. N. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0937-z · Cited by 317

Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis

Johnson, M., Stecher, B., Labrie, V., Brundin, L., & Brundin, P. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.09.007 · Cited by 320

S erum immune markers and disease progression in an incident P arkinson's disease cohort ( ICICLE‐PD )

Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 310

An inflammatory review of Parkinson's disease

Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309

The identity and function of microglia in neurodegeneration

Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308

CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease

Williams, G. P., Schonhoff, A. M., Jurkuvenaite, A., Corbin-Stein, N. J., Standaert, D. G., & Harms, A. S. (2021) · Brain · doi:10.1093/brain/awab103 · Cited by 319

The Therapeutic Potential of Metformin in Neurodegenerative Diseases

Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 316

Oxidative and Inflammatory Pathways in Parkinson’s Disease

Miller, R. L., James-Kracke, M., Sun, G. Y., & Sun, A. Y. (2009) · Neurochemical Research · doi:10.1007/s11064-008-9656-2 · Cited by 306

Injections of an opioid antagonist into the locus coeruleus and periaqueductal gray but not the amygdala precipitates morphine withdrawal in the 7‐day‐old rat

Jones, K. L., & Barr, G. A. (2000) · Synapse · doi:10.1002/1098-2396(200102)39:2 · Cited by 11

Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease

Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 313

Emerging therapies in Parkinson disease — repurposed drugs and new approaches

Elkouzi, A., Vedam‐Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 316

Expression of the histocompatibility glycoprotein HLA-DR in neurological disease

McGeer, P. L., Itagaki, S., & McGeer, E. G. (1988) · Acta Neuropathologica · doi:10.1007/bf00689592 · Cited by 420

HLA-DR reactive microglia in Parkinson's disease

Itagaki, S., McGeer, P. L., & McGeer, E. G. (1987) · Journal of Neuroimmunology · doi:10.1016/0165-5728(87)90252-9 · Cited by 5

Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR

McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90696-3 · Cited by 836

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791

Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain

Styren, S. D., Civin, W. H., & Rogers, J. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90054-v · Cited by 191